Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$0.69 USD
-0.01 (-1.40%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.69 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Atara Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 52 | 243 | 371 | 501 | 259 |
Receivables | 34 | 40 | 1 | 1 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 10 | 2 | 0 | 0 | 0 |
Other Current Assets | 6 | 10 | 12 | 21 | 14 |
Total Current Assets | 102 | 295 | 385 | 523 | 273 |
Net Property & Equipment | 4 | 6 | 54 | 51 | 54 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 7 | 4 | 2 | 2 |
Total Assets | 166 | 376 | 468 | 588 | 343 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 7 | 17 | 7 | 8 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 29 | 43 | 39 | 36 | 23 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 110 | 29 | 50 | 40 | 6 |
Total Current Liabilities | 142 | 79 | 106 | 83 | 37 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 38 | 77 | 56 | 28 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 39 | 36 | 2 | 2 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 265 | 250 | 189 | 126 | 52 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,870 | 1,822 | 1,745 | 1,587 | 1,109 |
Retained Earnings | -1,969 | -1,693 | -1,465 | -1,125 | -818 |
Other Equity | 0 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -99 | 127 | 280 | 462 | 291 |
Total Liabilities & Shareholder's Equity | 166 | 376 | 468 | 588 | 343 |
Total Common Equity | -99 | 127 | 280 | 462 | 291 |
Shares Outstanding | 101.90 | 94.80 | 88.40 | 77.70 | 54.10 |
Book Value Per Share | -0.97 | 1.34 | 3.16 | 5.95 | 5.37 |
Fiscal Year End for Atara Biotherapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 52 | 103 | 154 | 206 |
Receivables | NA | 34 | 0 | 1 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 10 | 7 | 8 | 5 |
Other Current Assets | NA | 6 | 9 | 10 | 13 |
Total Current Assets | NA | 102 | 119 | 172 | 224 |
Net Property & Equipment | NA | 4 | 5 | 5 | 6 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 6 | 7 | 7 |
Total Assets | NA | 166 | 189 | 246 | 302 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 7 | 4 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 29 | 38 | 33 | 33 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 110 | 34 | 37 | 30 |
Total Current Liabilities | NA | 142 | 79 | 75 | 68 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 38 | 74 | 76 | 78 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 38 | 37 | 36 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 265 | 240 | 239 | 237 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,870 | 1,858 | 1,847 | 1,834 |
Retained Earnings | NA | -1,969 | -1,909 | -1,839 | -1,768 |
Other Equity | NA | 0 | -1 | -1 | -1 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | -99 | -51 | 7 | 65 |
Total Liabilities & Shareholder's Equity | NA | 166 | 189 | 246 | 302 |
Total Common Equity | 0 | -99 | -51 | 7 | 65 |
Shares Outstanding | 119.30 | 101.90 | 101.90 | 97.90 | 96.60 |
Book Value Per Share | 0.00 | -0.97 | -0.50 | 0.08 | 0.67 |